drugset / Trial / NCT00961220

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

NCT00961220

Phase 1/2 Completed 17 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial studies the side effects and best dose of carmustine when given together with O6-benzylguanine and to see how well they work in treating patients with stage IA-IIA cutaneous T-cell lymphoma. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help carmustine work better by making cancer cells more sensitive to the drug. Giving O6-benzylguanine with carmustine may kill more cancer cells.

Timeline

Start
2010-02-01
Primary completion
2012-04-08
Completion
2014-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject O6-benzylguanine Small molecule 120 mg/m2 Intravenous
Subject carmustine Small molecule 20 mg Topical